CHMP Recommends Marketing Authorisation of the COVID-19 Vaccine Valneva also for Booster Vaccinations

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) recommended on 23 February 2023 that Valneva's inactivated, adjuvanted whole virus COVID-19 vaccine receive a marketing authorisation as a booster vaccine for adults aged 18 to 50. The vaccine has so far been authorised for the primary vaccination of individuals aged 18 to 50 years. The European Commission takes the decision the extension of the authorisation and generally follows the CHMP recommendation.